COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No

Chest

Volumn 150, Issue 2, 2016, Pages 276-278

  Brown, Kevin K ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PIRFENIDONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; TUMOR NECROSIS FACTOR;

COMORBIDITY; DISEASE SEVERITY; DRUG RESPONSE; EDITORIAL; EXERCISE TOLERANCE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MORTALITY RATE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; DECISION MAKING; DRUG TOLERANCE; SEVERITY OF ILLNESS INDEX;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DECISION MAKING; DRUG TOLERANCE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84981225532     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.04.036     Document Type: Editorial

References (14)

1. 1 Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and Safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2071–2082.
2. 2 King, T.E. Jr., Bradford, W.Z., Castro-Bernadini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2083–2092.
3. 3 The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2093–2101.
4. 4 Hunninghake, G.M., A new hope for idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2142–2143.
5. 5 Silverman, J.J., Talbot, T.J., Diffuse interstitial pulmonary fibrosis camouflaged by hypermetabolism and cardiac failure; antemortem diagnosis with biopsy and catheterization studies. Ann Intern Med 38:6 (1953), 1326–1338.
6. 6 Raghu, G., Collard, H.R., Anstrom, K.J., et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185:10 (2012), 1044–1048.
7. 7 Wells, A.U., Behr, J., Costabel, U., et al. Hot off the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 67:11 (2012), 938–940.
8. 8 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:9779 (2011), 1760–1769.
9. 9 Wells, A.U., Latsi, P., McCune, W.J., Daily cyclophosphamide for scleroderma: Are patients with the most to gain underrepresented in this trial?. Am J Respir Crit Care Med 176:10 (2007), 952–953.
10. 10 Raghu, G., Anstrom, K.J., King, T.E. Jr., Lasky, J.A., Martinez, F.J., Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366:21 (2012), 1968–1977.
11. 11 Schmidt, S.L., Tayob, N., Han, M.K., et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 145:3 (2014), 579–585.
12. 12 Raghu, G., Johnson, W.C., Lockhart, D., Mageto, Y., Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 159:4 Pt 1 (1999), 1061–1069.
13. 13 Dowman, L., Hill, C.J., Holland, A.E., Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev, 10, 2014, CD006322.
14. 14 Lee, J.S., Collard, H.R., Anstrom, K.J., et al., IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1:5 (2013), 369–376.